文献速递肝病

肝星状细胞自噬抑制细胞外囊泡释放从而减轻肝纤维化

Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
PubMed 文献 · J Hepatol · 2020-05-08

该研究探讨肝星状细胞(HSC)自噬对促纤维化细胞外囊泡(EV)释放的影响。体外实验使用原代人和小鼠HSC及LX2细胞,体内采用CCl4或胆管结扎小鼠模型。结果发现PDGF/SHP2通过mTOR信号抑制自噬并增加EV释放,HSC特异性敲除SHP2可减轻肝纤维化,循环EV传递该效应;肝硬化患者SHP2表达上调。

要点

  • PDGF/SHP2通过mTOR信号抑制HSC自噬,促进促纤维化EV释放
  • HSC特异性敲除SHP2可减轻CCl4或BDL诱导的小鼠肝纤维化
  • 来自SHP2敲除小鼠的循环EV可减轻受体小鼠肝纤维化

核心结论

  • 肝星状细胞自噬通过抑制促纤维化细胞外囊泡的释放来减轻肝纤维化。

研究设计与样本

  • 体外实验使用原代人及小鼠HSC和LX2细胞,小EV经差速超速离心纯化。
  • 体内采用CCl4或胆管结扎(BDL)诱导的小鼠肝纤维化模型。
  • 比较肝硬化患者与健康对照肝组织裂解物的RNA测序结果。

主要发现

  • PDGF及其下游分子SHP2抑制自噬并增加HSC来源的EV释放。
  • RNA测序鉴定出受SHP2和PDGF调控的mTOR信号分子。
  • 阻断mTOR信号可消除PDGF依赖的EV释放。
  • 激活mTOR信号通过抑制自噬诱导多囊体来源外泌体释放,通过激活ROCK1信号诱导微囊泡释放。
  • 这些mTOR依赖的EV在体外促进HSC迁移。

关键数值与推荐

  • HSC选择性敲除SHP2可减轻CCl4或BDL诱导的肝纤维化。
  • 在CCl4模型中,接受HSC特异性Shp2敲除小鼠循环EV的小鼠纤维化程度低于接受对照小鼠EV的小鼠。
  • 肝硬化患者中SHP2表达上调。

临床怎么用

  • 提示靶向HSC中SHP2/mTOR通路或促纤维化EV释放可能成为抗肝纤维化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Autophagy plays a crucial role in hepatic homeostasis and its deregulation has been associated with chronic liver disease. However, the effect of autophagy on the release of fibrogenic extracellular vesicles (EVs) by platelet-derived growth factor (PDGF)-stimulated hepatic stellate cells (HSCs) remains unknown. Herein, we aimed to elucidate the role of autophagy, specifically relating to fibrogenic EV release, in fibrosis. METHODS: In vitro experiments were conducted in primary human and murine HSCs as well as LX2 cells. Small EVs were purified by differential ultracentrifugation. Carbon tetrachloride (CCl4) or bile duct ligation (BDL) were used to induce fibrosis in our mouse model. Liver lysates from patients with cirrhosis or healthy controls were compared by RNA sequencing. RESULTS: In vitro, PDGF and its downstream molecule SHP2 (Src homology 2-containing protein tyrosine phosphatase 2) inhibited autophagy and increased HSC-derived EV release. We used this PDGF/SHP2 model to further investigate how autophagy affects fibrogenic EV release. RNA sequencing identified an mTOR (mammalian target of rapamycin) signaling molecule that was regulated by SHP2 and PDGF. Disruption of mTOR signaling abolished PDGF-dependent EV release. Activation of mTOR signaling induced the release of multivesicular body-derived exosomes (by inhibiting autophagy) and microvesicles (by activating ROCK1 signaling). These mTOR-dependent EVs promoted in vitro HSC migration. To assess the importance of this mechanism in vivo, SHP2 was selectively deleted in HSCs, which attenuated CCl4- or BDL-induced liver fibrosis. Furthermore, in the CCl4 model, mice receiving circulating EVs derived from mice with HSC-specific Shp2 deletion had less fibrosis than mice receiving EVs from control mice. Correspondingly, SHP2 was upregulated in patients with liver cirrhosis. CONCLUSION: These results demonstrate that autophagy in HSCs attenuates liver fibrosis by inhibiting the release of fibrogenic EVs. LAY SUMMARY: During liver fibrosis and cirrhosis, activated hepatic stellate cells (HSCs) are the key cell type responsible for fibrotic tissue deposition. Recently, we demonstrated that activated HSCs release nano-sized vesicles enriched with fibrogenic proteins. In the current study, we unveil the mechanism by which these fibrogenic vesicles are released, moving a step closer to the long-term goal of therapeutically targeting this process.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gao J, Wei B, de Assuncao TM, et al. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. J Hepatol. 2020. PMID: 32389810. doi:10.1016/j.jhep.2020.04.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。